Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antiviral
Biotech
Traws defers midphase flu study after negative regulatory review
Regulators issued a “negative review” of Traws' planned flu challenge study, forcing the biotech to defer a phase 2a tied to $20 million in funding.
Nick Paul Taylor
Jun 15, 2026 9:19am
US taps small biotech for experimental Ebola treatment
May 20, 2026 7:18pm
Sanofi backs Altesa's $75M series B to bankroll rhinovirus study
Feb 19, 2026 7:00am
Merck pays $9.2B for owner of flu antiviral J&J rejected
Nov 14, 2025 8:25am
Gilead pumps up virology pipeline with drug transporter deal
Sep 29, 2025 10:35am
Enanta sees RSV drug fail phase 2b but finds positives
Sep 29, 2025 8:05am
